ACE and acute coronary syndrome: Seven toxin-derived products are approved by FDA [2], including angiotensin converting enzyme (ACE) inhibitor captopril from the venom of Bothrops jararaca for the treatment of hypertension [14], antiplatelet drug eptifibatide for the treatment of acute coronary syndrome [15,16], ziconotide designed from ω-conotoxin MVIIA for pain treatment [17,18], and a Gila-monster toxin derivative for treatment of type II diabetes (Byetta®, AstraZeneca, London, UK) [13].